Delving into the Latest Updates on BIO-203 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

PPARα

Mechanism

PPARα agonists(Peroxisome proliferator-activated receptor α agonists)

Therapeutic Areas

Congenital DisordersEye Diseases

Active Indication-

Inactive Indication

dry age-related macular degeneration

Originator Organization

Biophytis SA

Active Organization-

Inactive Organization

Université Pierre et Marie Curie

Institut de la Vision

Biophytis SA

Drug Highest PhaseDiscontinuedDiscovery

First Approval Date-

Regulation-

9'-cis-norbixin (norbixin/BIO201) protects RPE cells against phototoxicity induced by blue light and N-retinylidene-N-retinylethanolamine (A2E) in vitro and preserves visual functions in animal models of age-related macular degeneration (AMD) in vivo. The purpose of this study was to examine the mode of action and the in vitro and in vivo effects of BIO203, a novel norbixin amide conjugate. Compared to norbixin, BIO203 displays improved stability at all temperatures tested for up to 18 months. In vitro, BIO203 and norbixin share a similar mode of action involving the inhibition of PPARs, NF-κB, and AP-1 transactivations. The two compounds also reduce IL-6, IL-8, and VEGF expression induced by A2E. In vivo, ocular maximal concentration and BIO203 plasma exposure are increased compared to those of norbixin. Moreover, BIO203 administered systemically protects visual functions and retinal structure in albino rats subjected to blue-light illumination and in the retinal degeneration model of Abca4^-/- Rdh8^-/- double knock-out mice following 6 months of oral complementation. In conclusion, we report here that BIO203 and norbixin share similar modes of action and protective effects in vitro and in vivo. BIO203, with its improved pharmacokinetic and stability properties, could be developed for the treatment of retinal degenerative diseases such as AMD.

100 Deals associated with BIO-203

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
dry age-related macular degeneration	Discovery	FR	Biophytis SA	-
dry age-related macular degeneration	Discovery	FR	Biophytis SA	-
dry age-related macular degeneration	Discovery	FR	Université Pierre et Marie Curie	-
dry age-related macular degeneration	Discovery	FR	Institut de la Vision	-
dry age-related macular degeneration	Discovery	FR	Université Pierre et Marie Curie	-
dry age-related macular degeneration	Discovery	FR	Institut de la Vision	-